

## Richard Haynes

---

**From:** CambridgeEast.REC@hra.nhs.uk <noreply@harp.org.uk>  
**Sent:** 15 September 2020 16:44  
**To:** peter.horby@ndm.ox.ac.uk; ctrg@admin.ox.ac.uk; Richard Haynes  
**Cc:** nhsg.nrspcc@nhs.net; research.amendments@hscni.net;  
HCRW.amendments@wales.nhs.uk  
**Subject:** 20/EE/0101/AM10 IRAS 281712. Amendment categorisation and implementation information  
**Attachments:** 20EE0101AM10 , IRAS Project ID 281712 SL27  
\_Acknowledgement\_of\_a\_valid\_notice\_of\_a\_substantial\_amendment.pdf

### Amendment Categorisation and Implementation Information

Dear Horby

<b>IRAS Project ID:</b>	<b>281712</b>
<b>REC Reference:</b>	<b>20/EE/0101</b>
<b>Short Study Title:</b>	<b>RECOVERY trial [COVID-19] [UPH]</b>
<b>Date complete amendment submission received:</b>	<b>15 September 2020</b>
<b>Sponsor Amendment Reference Number:</b>	<b>Substantial Amendment 8</b>
<b>Sponsor Amendment Date:</b>	<b>10 September 2020</b>
<b>Amendment Type</b>	Substantial
<b>Outcome of HRA and HCRW Assessment</b>	<b>HRA and HCRW Approval for the amendment is pending</b> - HRA and HCRW Approval for the amendment will be separately confirmed by email.
<b>Implementation date in NHS organisations in England and Wales</b>	<b>03 days from date of HCRW Approval</b>
<b>Implementation date in NHS/HSC organisations in Northern Ireland, and/or Scotland</b>	<b>03 days from date of HCRW Approval</b>
For NHS/HSC R&D Office information	

<b>Amendment Category</b>	<b>A</b>
---------------------------	----------

Thank you for submitting an amendment to your project. We have now categorised your amendment and please find this, as well as other relevant information, in the table above.

### **What should I do next?**

Please read the information in [IRAS](#), which provides you with information on how and when you can implement your amendment at NHS/HSC sites in each nation, and [what actions you should take now](#).

If you have participating NHS/HSC organisations in any other UK nations please note that **we will** forward the amendment submission to the relevant national coordinating function(s).

If not already provided, please email to us any regulatory approvals (where applicable) once available.

### **When can I implement this amendment?**

You may implement this amendment in line with the information in [IRAS](#). Please note that you may only implement changes described in the amendment notice.

### **Who should I contact if I have further questions about this amendment?**

If you have any questions about this amendment please contact the relevant national coordinating centre for advice:

- England – [amendments@hra.nhs.uk](mailto:amendments@hra.nhs.uk)
- Northern Ireland – [research.gateway@hscni.net](mailto:research.gateway@hscni.net)
- Scotland – [nhsq.NRSPCC@nhs.net](mailto:nhsq.NRSPCC@nhs.net)
- Wales – [HCRW.amendments@wales.nhs.uk](mailto:HCRW.amendments@wales.nhs.uk)

Additional information on the management of amendments can be found in the [IRAS guidance](#).

Please do not hesitate to contact me if you require further information.

Kind regards

**Joy Uzoma**

**Health Research Authority**

Ground Floor | Skipton House | 80 London Road | London | SE1 6LH

**E.** [amendments@hra.nhs.uk](mailto:amendments@hra.nhs.uk)

**W.** [www.hra.nhs.uk](http://www.hra.nhs.uk)

Sign up to receive our newsletter [HRA Latest](#).